Rakovina Therapeutics Inc. (RKV.V)

0.0850 -0.0050 (-5.56%) At close: 12:01PM EDT

Rakovina Therapeutics Inc.

1008 Beach Avenue
Suite 105
Vancouver, BC V6E 1T7
Canada

https://www.rakovinatherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Jeffrey A. Bacha B.Sc., M.B.A.	Executive Chairman	120k	N/A	1968
Mr. David Hyman CA, CBV	CFO & Corporate Secretary	120k	N/A	1973
Dr. Mads Daugaard	President, CEO & Chief Scientific Officer	N/A	N/A	N/A
Dr. John Langlands Ph.D.	Chief Operating Officer	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in CAD.

Description

Rakovina Therapeutics Inc. engages in the research and development of new cancer treatments based on novel series of small-molecule DNA-damage response inhibitors (DDRi). Its preclinical product pipeline include kt-2000, a next generation oral targeted small molecule PARP inhibitors; kt-3000, a bi-functional small-molecule drug candidate; and kt-4000, a DNA-damaging DDR inhibitors. Rakovina Therapeutics Inc. was formerly known as Vincero Capital Corp. The company is headquartered in Vancouver, Canada.

Corporate Governance

Rakovina Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.